Categories
Change Password!
Reset Password!
Buspirone use in Williams syndrome lowers anxiety severity without any safety concerns.
In a study by Robyn P. Thom et al., buspirone demonstrated the potential to reduce anxiety severity in individuals with Williams syndrome while maintaining a favorable safety and tolerability profile. This 16-week, prospective, open-label trial determined the effectiveness, safety, and tolerability of buspirone in 20 patients (aged 5–65 years) suffering from Williams syndrome.
Pediatric anxiety rating scale (PARS) was the primary outcome measure. Participants received a flexible buspirone dose (mean: 22.6 mg/day), leading to a significant reduction in anxiety severity (Cohen’s d = -4.02). All 18 participants who completed the study were assessed as "much improved" or "very much improved" on the Clinical Global Impression-Improvement subscale for anxiety.
No serious or severe adverse events were witnessed. Furthermore, no participants withdrew due to adverse effects. These findings suggest buspirone is safe, effective, and well-tolerated in Williams syndrome, supporting the need for double-blind, placebo-controlled trials to confirm its benefits.
Journal of Child and Adolescent Psychopharmacology
A Prospective Open-Label Trial of Buspirone for the Treatment of Anxiety in Williams Syndrome
Robyn P. Thom et al.
Comments (0)